top of page

Physicians
Patients
- AutoBMD Patients
- AICAC Patients
Knowledge Center
News
About Us
More

Use tab to navigate through the menu items.

HeartLung Receives FDA “Breakthrough” Designation and Marketing Authorization for the First AI to Enable Opportunistic Detection of Hidden Heart Disease in Millions of CT Scans

News and Updates

HeartLung’s 2024 Year in Review - Milestones and Pipeline for 2025

5 hours ago5 min read

HeartLung’s 2024 Year in Review - Milestones and Pipeline for 2025

2024 was a monumental year for HeartLung Technologies. With that being said, we have exciting developments for 2025!

HeartLung's distinguished advisor, Dr. Claudia Henschke, who pioneered lung cancer screening, wins the RSNA 2024 Scientific Excellence Award 🏆⚕️

Dec 11, 20241 min read

HeartLung's distinguished advisor, Dr. Claudia Henschke, who pioneered lung cancer screening, wins the RSNA 2024 Scientific Excellence Award 🏆⚕️

HeartLung collaborator, Dr. Claudia Henschke, has been honored with the prestigious Scientific Excellence Award at #RSNA2024!

HeartLung Technologies to Present Four Scientific Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at the 2024 Radiological Society of North America (RSNA 2024)

Dec 2, 20244 min read

HeartLung Technologies to Present Four Scientific Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at the 2024 Radiological Society of North America (RSNA 2024)

HeartLung is the only AI company participating in RSNA 2024 as a scientific presenter of research studies and as an industry exhibitor

HeartLung Technologies Presented AI-CAC™ and AI-CVD™ Research Studies at the Annual Scientific Sessions of the American Heart Association 2024

Nov 18, 20244 min read

HeartLung Technologies Presented AI-CAC™ and AI-CVD™ Research Studies at the Annual Scientific Sessions of the American Heart Association 2024

Innovative AI-enabled research studies led by HeartLung’s founder Dr. Morteza Naghavi show life-saving potential for primary prevention...

HeartLung Technologies Receives FDA “Breakthrough” Designation and Marketing Authorization for AutoChamber™

Oct 28, 20248 min read

HeartLung Technologies Receives FDA “Breakthrough” Designation and Marketing Authorization for AutoChamber™

The First AI that Enables Opportunistic Detection of Hidden Heart Disease in Millions of CT Scans SUMMARY: HeartLung Technologies (...

1

2

Updates from 'X' (Twitter)

Contact Us Today

We'd love to hear from you. Please fill this form to request more information.

I'm interested in:

I’m interested in AutoBMD™ AI

I’m interested in AutoChamber™ AI

I’m interested in AI-CAC™

I’m interested in AI-CVD™

I’m interested in AUTO10™

I’m interested in representing HeartLung

How did you hear about us?

Email Marketing

Medical Conference

Social Media

Google Search

Referred by Colleague/Friend

Other

First Name

Email

Last Name

Phone

Hospital/Institution

Thank you for your interest.

A HeartLung representative will contact you as soon as possible!

Contact

contact@heartlung.ai

Company

HeartLung Corporation

Resources

Knowledge Center
FAQ

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

©2025 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686. and Patents Pending. AutoBMD™, AutoCAC™, AutoChamber™ and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page